Tag: biotech funding
-
Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria
Overview: A Major Step Forward in Global Health The Gates Foundation has announced a significant investment in bioscience aimed at accelerating the development of new vaccines using the next-generation srRNA (self-replicating RNA) platform. The funding, totaling approximately $7 million, will support researchers as they advance antigen designs for malaria and HIV vaccines. This initiative seeks…
-
Bioscience Secures Gates Foundation Grant to Advance srRNA Vaccines for HIV and Malaria
Overview Bioscience has been awarded approximately $7 million in funding from the Gates Foundation to advance its novel srRNA vaccine platform for HIV and malaria. The grant supports the development of candidate vaccines aimed at addressing two of the world’s most persistent public health burdens. The funding is contingent on humanitarian licensing terms, underscoring a…
-
Vasomune expands with AnGes partnership to broaden vascular damage therapy indications
Vasomune and AnGes announce expanded collaboration The Sunnybrook-based start-up Vasomune Therapeutics has strengthened its strategic alliance with Japanese biopharma company AnGes. The expanded partnership aims to broaden the indications for Vasomune’s lead drug candidate, which targets vascular damage and related cardiovascular conditions. The agreement comes with a $4 million funding commitment designed to accelerate development…
-
Vasomune Expands Partnership with AnGes to Advance Vascular Damage Drug Candidate
Overview: A Strategic Expansion in Vascular Therapy Sunnybrook-based startup Vasomune Therapeutics is broadening its collaboration with pharmaceutical giant AnGes to expand the indications for their leading drug candidate designed to treat vascular damage. The new agreement injects $4 million in funding to accelerate development, clinical milestones, and regulatory progress as the two companies pursue improved…
-
MS Research Derailed by Stock Market Spoofing: Lawsuit Reveals Market Manipulation Impact
Introduction: A Promising MS Breakthrough Put at Risk A Canadian biotechnology company pursuing a groundbreaking multiple sclerosis (MS) treatment has filed a lawsuit alleging that stock market spoofing and related manipulation behaviors derailed its research funding and strategic decisions. This unfolding case, the first in a series by a W5 investigation, shines a harsh light…
-
Knut Steffensen Leads Karolinska ATMP Center to Bring Therapies to Patients
Moving cell and gene therapy from lab to patient care The Karolinska Institutet is establishing a dedicated ATMP Center to accelerate the development of advanced therapy medicinal products (ATMPs) and to close the gaps between discovery, manufacturing, and clinical delivery. Led by Knut Steffensen, the center aims to function as a “virtual hub” where researchers,…